Showing results (21-30 of 95) with videos related to

Sort By:
Pageof 10
European Journal of Nuclear Medicine and Molecular Imaging|February 23, 2018
Pre-dosing with lilotomab prior to therapy with <sup>177</sup>Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patientsCaroline Stokke, Johan Blakkisrud, Ayca Løndalen, et al.
Cytometry. Part B, Clinical Cytometry|December 10, 2016
Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell PopulationsCara Ellen Wogsland, Allison Rae Greenplate, Arne Kolstad, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 16, 2020
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of <sup>177</sup>Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphomaAyca Løndalen, Johan Blakkisrud, Mona-Elisabeth Revheim, et al.
Seminars in Nuclear Medicine|January 12, 2023
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An updateFrancesco Cicone, Giulia Santo, Caroline Bodet-Milin, et al.
Plos One|March 19, 2020
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003Astri Fjelde Maaland, Amal Saidi, Julien Torgue, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2015
Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myelomaEgil S Blix, Anders B Kildal, Eirin Bertelsen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 17, 2019
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate <sup>177</sup>Lu-NNV003Astri Fjelde Maaland, Helen Heyerdahl, Adam O'Shea, et al.
Pharmaceuticals (Basel, Switzerland)|February 27, 2026
A Phase II Study of <sup>177</sup>Lu-Lilotomab Satetraxetan, a CD37 Antibody-Radionuclide Conjugate, as Third- or Later-Line Treatment of Rituximab-Refractory Follicular B-Cell Lymphoma PatientsRoy H Larsen, Arne Kolstad, Alexander Fosså, et al.
Acta Oncologica (Stockholm, Sweden)|November 19, 2013
Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphomaHanne Bersvendsen, Arne Kolstad, Anne Kirsti Blystad, et al.
Leukemia & Lymphoma|January 18, 2014
High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab eraYngvild N Blaker, Marianne B Eide, Knut Liestøl, et al.
Pageof 10